Table 3.
Clinical events by treatment arm
| Ergocalciferol (n=137) | Placebo (n=139) | P Value | ||
|---|---|---|---|---|
| All-cause hospitalization | ||||
| Events/total years at risk | 70/61.1 | 88/62.6 | ||
| Event rate (per 100 PY) (95% CI) | 114.6 (90.7 to 144.8) | 140.5 (114.0 to 173.1) | ||
| IRR (95% CI) | 0.82 (0.60 to 1.12) | 1.00 (Reference) | 0.20 | |
| Cardiovascular disease hospitalization | ||||
| Events/total years at risk | 17/61.1 | 29/62.6 | ||
| Event rate (per 100 PY) (95% CI) | 27.8 (17.3 to 44.8) | 46.3 (32.2 to 66.6) | ||
| IRR (95% CI) | 0.60 (0.33 to 1.09) | 1.00 (Reference) | 0.10 | |
| Infection-related hospitalization | ||||
| Events/total years at risk | 15/61.1 | 15/62.6 | ||
| Event rate (per 100 PY) (95% CI) | 24.6 (14.8 to 40.7) | 23.9 (14.4 to 39.7) | ||
| IRR (95% CI) | 1.03 (0.50 to 2.10) | 1.00 (Reference) | 0.95 | |
| Falls | ||||
| Events/total years at risk | 21/61.1 | 21/62.6 | ||
| Event rate (per 100 PY) (95% CI) | 34.4 (22.4 to 52.7) | 33.5 (21.9 to 51.4) | ||
| IRR (95% CI) | 1.03 (0.56 to 1.88) | 1.00 (Reference) | 0.94 | |
| Fractures | ||||
| Events/total years at risk | 5/61.1 | 1/62.6 | ||
| Event rate (per 100 PY) (95% CI) | 8.2 (3.4 to 19.7) | 1.6 (0.2 to 11.3) | ||
| IRR (95% CI) | 5.13 (0.60 to 43.88) | 1.00 (Reference) | 0.14 | |
PY, person-years; IRR, Incidence rate ratio is the ratio of the event rate in the ergocalciferol as compared with the placebo arm.